Stay updated with breaking news from Cure limited. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NovoCure Limited (NASDAQ:NVCR – Get Free Report) Director W Anthony Vernon sold 964 shares of the business’s stock in a transaction on Tuesday, June 4th. The shares were sold at an average price of $23.89, for a total transaction of $23,029.96. Following the sale, the director now owns 164,833 shares of the company’s stock, valued […] ....
NovoCure Limited (NASDAQ:NVCR – Get Free Report) Director W Anthony Vernon sold 964 shares of the business’s stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $23.89, for a total value of $23,029.96. Following the sale, the director now owns 164,833 shares of the company’s stock, valued […] ....
Rhenman & Partners Asset Management AB bought a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 160,000 shares of the medical equipment provider’s stock, valued at approximately $2,389,000. Rhenman & Partners Asset Management AB […] ....
Rhenman & Partners Asset Management AB bought a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 160,000 shares of the medical equipment provider’s stock, valued at approximately $2,389,000. Rhenman & Partners Asset Management AB […] ....
NovoCure Limited (NASDAQ:NVCR – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 […] ....